Appendix

Table A1 Concentration-response functions for ozone-related health endpoints

Endpoint	Population	Impact category	ERF	C.I.95% low	C.I.95% high
Morbidity	Entire age groups	Respiratory hospital admissions < 65	3.54E−06	6.12E−07	6.47E−06
	Adults	Respiratory hospital admissions 65 +	1.25E−05	−5.00E−06	3.00E−05
	Adults	Bronchodilator usage	1.04E−02	−3.64E−03	2.24E−02
	Adults	Lower respiratory symptoms	2.29E−03	−6.14E−03	1.16E−02
	Adults	Asthma	4.29E−03	3.30E−04	8.25E−03
	Adults	Minor restricted activity day	1.15E−02	4.40E−03	1.86E−02
	Adults	Consultation for allergic rhinitis	1.60E−04	1.22E−04	2.03E−04
	Children	Consultation for allergic rhinitis	3.03E−04	1.89E−04	4.29E−04
	Children	Cough	9.30E−02	−1.90E−02	2.22E−01
	Children	Lower respiratory symptoms(wheeze)	1.60E−02	−4.30E−02	8.10E−02
	Children	Consultation for allergic rhinitis	3.03E−04	1.89E−04	4.29E−04
	Adults	Consultation for allergic rhinitis	1.60E−04	1.22E−04	2.03E−04
	Children	Acute respiratory symptoms days	9.30E−02	−1.90E−02	2.22E−01
	Adults	Acute respiratory symptoms days	1.60E−02	−4.30E−02	8.10E−02
Mortality	Adult 30 +	Mortality from chronic exposure	2.00E−03	6.50E−04	3.35E−03
Work loss	Adults	Work loss day	4.13E−03	1.65E−03	6.63E−03
VSL	Entire age groups	Value of statistical life (million USD)	2.50E−01		

Notes: Source (Bickel et al., 2005; Amann, 2008; Jin, 2017; Turner et al., 2016).

Table A2 Concentration-response functions for $PM_{2.5}$-related health endpoints

Category	Population	Endpoint	Medium	C.I. (95%) Low	C.I. (95%) High
Morbidity	Adult	Work loss day	0.0207	0.0176	0.0238
	All ages	Respiratory hospital admissions	1.17E–05	6.38E–06	1.72E–05
	Adult	Cerebrovascular hospital admission	8.4E–06	6.47E–07	1.16E–05
	Adult	Cardiovascular hospital admissions	7.23E–06	3.62E–06	1.09E–05
	Age 27 +	Chronic bronchitis	4.42E–05	–1.8E–06	9.02E–05
	All ages	Asthma attacks	0.000122	4.33E–05	0.001208
	All ages	Respiratory symptoms days	0.217	0.025	0.405
Mortality	Age 30 +	All cause	0.004	0.0003	0.008

Notes: Source (Pope et al., 2002; Bickel et al., 2005; Apte et al., 2015).

References

Amann M (2008). Health Risks of Ozone from Long-Range Transboundary Air Pollution. Copenhagen: WHO Regional Office Europe

Apte J S, Marshall J D, Cohen A J, Brauer M (2015). Addressing global mortality from ambient $PM_{2.5}$. Environmental Science & Technology, 49(13): 8057–8066

Bickel P, Friedrich R, Droste-Franke B, Bachmann T, Gressmann A, Rabl A, Hunt A, Markandya A, Tol R, Hurley F (2005). ExternE Externalities of Energy Methodology 2005 Update. Luxembourg: Office for Official Publications of the European Communities

Jin Y, Andersson H, Zhang S (2017). China's cap on coal and the efficiency of local interventions: A benefit-cost analysis of phasing out coal in power plants and in households in Beijing. Journal of Benefit-Cost Analysis, 8 (2): 147–186

Pope C A 3rd, Burnett R T, Thun M J, Calle E E, Krewsk i D, Ito K, Thurston G D (2002). Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. Journal of the American Medical Association, 287(9): 1132–1141

Turner M C, Jerrett M, Pope C A 3rd, Krewski D, Gapstur S M, Diver W R, Beckerman B S, Marshall J D, Su J, Crouse D L, Burnett R T (2016). Long-term ozone exposure and mortality in a large prospective study. American Journal of Respiratory and Critical Care Medicine, 193(10): 1134–1142